Command Palette

Search for a command to run...

VENUSREM

456.35-0.88%
Market Cap
₹616.22 Cr
Stock P/E
11.47
ROCE
13.17%
ROE
8.64%
Book Value
₹426.83

Financials

YoY Net Sales
EPS Growth
Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings
Distribution
Promoter
Institution
Public
Others

From Last Concall

No Concall Summary

Conference call summary is not available for this stock.

Peers Summary

Sector Leader

Venus Remedies Ltd. presents a competitive valuation and solid growth metrics compared to its peers in the pharmaceuticals sector. While it has the lowest PE ratio along with strong cash flow metrics, some peers exhibit better profitability and growth. Companies like Mankind Pharma and Dr. Reddy's demonstrate superior growth, while Divi's Laboratories stands out for its profitability despite a high PE ratio.

Key Points
  • Venus Remedies shows strong cash flow metrics with a debt-equity ratio of 0.003.
  • Lowest PE ratio among peers, indicating potential undervaluation.
  • Mankind Pharma and Dr. Reddy's Laboratories exhibit the highest growth metrics.
Top Performers
Dr. Reddy's Laboratories Ltd.

Best profitability with high ROE and strong growth metrics.

Mankind Pharma Ltd.

Highest revenue growth YoY and over the past three years, showcasing strong market performance.

Cipla Ltd.

Solid profitability metrics and reasonable valuation ratios.

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.